---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037193"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:53:13.950137+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports FY2021 record revenue of $63.1M, net loss of $44.0M; DFD-29 Phase 3 underway

## Summary
- Record net product revenues of $63.1M in FY2021, up 42% from $44.5M in FY2020.
- Net loss attributable to common stockholders of $44.0M ($4.32/share) vs net income of $5.3M ($0.58/share) in FY2020.
- Non-GAAP adjusted EBITDA positive at $2.9M; non-GAAP net loss of $16.9M ($1.66/share).
- Cash and equivalents $49.1M at Dec 31, 2021, up from $8.2M a year ago, boosted by IPO proceeds.
- Dosed first patient in Phase 3 for DFD-29 for rosacea; received $10M milestone from Maruho; acquired VYNE MST franchise for $20M.

## SEC filing metadata
- accession: 0001104659-22-037193
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465922037193/0001104659-22-037193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465922037193/tm2210106d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037193
- JSON: https://secwatch.observer/filing/0001104659-22-037193.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.